European Archives - Page 935 of 1020 - European Medical Journal

Continue
EMJ
15 Oct 2015

New approaches to molecular cancer therapeutics

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
EMJ
15 Oct 2015

The Patient Reported Opinions about Clinical Tolerability (PROACT)

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient…
EMJ
15 Oct 2015

EURECCA international comparison of treatment patterns for non-metastatic breast cancer

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…
EMJ
15 Oct 2015

Results from the ETOP Lungscape Project: Multiplex mutation testing in NSCLC

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the…
EMJ
15 Oct 2015

The causes and consequences of tumour evolution and heterogeneity

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
EMJ
15 Oct 2015

Patient-centered partnership improve access to optimal standards of cancer care in Europe

European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40…
EMJ
15 Oct 2015

ECC 2015: Press programme with updates on ‘Europe of Disparities in Cancer’

At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queen’s University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College…
EMJ
15 Oct 2015

The discovery of new biomarkers for predicting outcomes in breast cancer

In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to…
EMJ
15 Oct 2015

First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in…
EMJ
15 Oct 2015

Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC

At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis…